NEXIMMUNE (NEXI) Financials
Newest figures come from the 10-Q for Q2 FY2024, filed Aug 7, 2024. Each column of the statement tables below links to the filing it was taken from.
This page shows NEXIMMUNE INC (NEXI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
NEXIMMUNE INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
NEXIMMUNE INC passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
NEXIMMUNE INC reported a net loss of $32.3M while operations used $31.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
NEXIMMUNE INC's EBITDA was -$3.4M in Q2 2024, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NEXIMMUNE INC reported a net loss of $2.3M in Q2 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NEXIMMUNE INC earned -$1.69 per diluted share (EPS) in Q2 2024. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2024.
Cash & Balance Sheet
NEXIMMUNE INC recorded an outflow of $2.1M in free cash flow in Q2 2024, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NEXIMMUNE INC held $2.4M in cash as of Q2 2024; no long-term debt figure is on record for that period.
Not reported for Q2 2024.
Margins & Returns
NEXIMMUNE INC's quarterly ROE was -334.1% in Q2 2024: one quarter's net income over shareholder equity, not annualized. This is down 289.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 221.9 percentage points.
Not reported for Q2 2024.
Not reported for Q2 2024.
Not reported for Q2 2024.
Capital Allocation
NEXIMMUNE INC invested $647K in research and development in Q2 2024. This represents a decrease of 86.7% from the same quarter a year earlier. Against the prior quarter it is down 13.0%.
NEXIMMUNE INC reported no capital expenditure in Q2 2024. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2024.
NEXI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| R&D Expenses | $647K-86.7% | $744K-87.9% | N/A | $6.0M-46.1% | $4.9M-58.8% | $6.1M-41.4% | N/A | $11.1M-1.7% |
| SG&A Expenses | $2.1M-28.3% | $2.0M-45.6% | N/A | $4.0M+7.3% | $2.9M-29.0% | $3.7M-19.6% | N/A | $3.7M-10.6% |
| Operating Income | -$3.5Mn/m | -$2.8Mn/m | N/A | -$10.0Mn/m | -$7.8Mn/m | -$9.8Mn/m | N/A | -$14.9Mn/m |
| EBITDA | -$3.4Mn/m | -$2.6Mn/m | N/A | -$9.7Mn/m | -$7.5Mn/m | -$9.6Mn/m | N/A | -$14.6Mn/m |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Income Tax | $0n/m | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m |
| Net Income | -$2.3Mn/m | -$3.1Mn/m | N/A | -$9.9Mn/m | -$7.6Mn/m | -$9.6Mn/m | N/A | -$14.7Mn/m |
| EPS (Basic) | -$1.69 | -$2.46 | -$4.99 | -$9.40 | -$7.25 | -$9.17 | -$0.65n/m | -$15.09 |
| EPS (Diluted) | -$1.69 | -$2.46 | -$4.99 | -$9.40 | -$7.25 | -$9.17 | -$0.65n/m | -$15.09 |
| Diluted Shares (Avg) | 1M | 1M | N/A | 1M | 1M | 1M | N/A | 976,413 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
NEXI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.9M-75.0% | $9.0M-70.7% | $8.6M-80.0% | $14.6M-74.8% | $23.5M-64.3% | $30.7M-60.8% | $43.1M-52.7% | $57.7M-44.8% |
| Current Assets | $3.1M-83.1% | $6.0M-76.2% | $5.4M-85.5% | $10.3M-80.2% | $18.5M-69.0% | $25.4M-64.7% | $37.4M-56.7% | $52.0M-47.3% |
| Cash & Equivalents | $2.4M-85.1% | $4.5M-80.0% | $3.2M-90.8% | $9.0M-80.4% | $16.3M-59.9% | $22.3M-8.9% | $34.6M+14.2% | $45.9M+23.1% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $4.9M-23.7% | $6.0M-15.0% | $5.1M-52.7% | $6.3M-36.7% | $6.5M-34.1% | $7.1M-10.5% | $10.8M+48.0% | $10.0M+34.0% |
| Current Liabilities | $4.7M-24.4% | $4.6M-31.7% | $5.1M-50.8% | $6.2M-34.0% | $6.3M-31.2% | $6.8M-4.3% | $10.3M+43.2% | $9.4M+26.4% |
| Non-Current Liabilities | $204K+0.1% | $1.4M+362.8% | $0-100.0% | $103K-81.8% | $204K-70.9% | $300K-63.8% | $426K+666.0% | $565Kn/m |
| Long-Term Debt | N/A | N/A | $0n/m | N/A | N/A | N/A | $0 | N/A |
| Total Equity | $696K-95.9% | $2.7M-88.4% | $3.5M-89.1% | $8.3M-82.7% | $17.0M-69.6% | $23.6M-66.5% | $32.3M-61.4% | $47.7M-50.9% |
| Retained Earnings | -$228.0Mn/m | -$225.7Mn/m | -$222.6Mn/m | -$217.2Mn/m | -$207.4Mn/m | -$199.8Mn/m | -$190.2Mn/m | -$173.4Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
NEXI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1Mn/m | -$2.4Mn/m | -$5.8Mn/m | -$7.3Mn/m | -$6.0Mn/m | -$12.3Mn/m | -$11.1Mn/m | -$11.9Mn/m |
| Depreciation & Amortization | $75K-71.8% | $115K-56.4% | $229K-13.5% | $266K+1.8% | $267K+10.0% | $264K+16.2% | $264K+8.6% | $261K+11.9% |
| Stock-Based Compensation | $281K-71.7% | $348K-58.7% | N/A | $1.1M-23.1% | $991K-24.3% | $842K-48.8% | N/A | $1.4M-11.7% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $0-100.0% | $981-99.8% | $5K-96.0% | $43K-87.6% | $224K-56.6% | $563K+181.2% |
| Free Cash Flow | -$2.1Mn/m | -$2.4Mn/m | -$5.8Mn/m | -$7.3Mn/m | -$6.0Mn/m | -$12.3Mn/m | -$11.3Mn/m | -$12.4Mn/m |
| Investing Cash Flow | $44Kn/m | $523Kn/m | $0n/m | $3K-100.0% | -$5K-100.0% | -$43K-100.4% | -$143K-103.6% | $11.9Mn/m |
| Financing Cash Flow | $0n/m | $3.1Mn/m | $0n/m | $0-100.0% | $0n/m | $0-100.0% | $0-100.0% | $5.1M+2314.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NEXI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -334.1%-289.6pp | -112.2%-71.6pp | N/A | -119.4%-88.5pp | -44.5%-16.1pp | -40.6%-19.2pp | N/A | -30.9%-15.8pp |
| Return on Assets | -39.7%-7.5pp | -34.2%-3.0pp | N/A | -67.7%-42.1pp | -32.2%-8.1pp | -31.2%-12.0pp | N/A | -25.5%-11.5pp |
| Current Ratio | 0.66-2.3x | 1.30-2.4x | 1.06-2.6x | 1.66-3.9x | 2.95-3.6x | 3.74-6.4x | 3.62-8.3x | 5.54-7.7x |
| Debt-to-Equity | N/A | N/A | 0.000.0x | N/A | N/A | N/A | 0.00 | N/A |
| Liabilities-to-Equity | 7.10+6.7x | 2.20+1.9x | 1.45+1.1x | 0.76+0.6x | 0.38+0.2x | 0.30+0.2x | 0.33+0.2x | 0.21+0.1x |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NEXIMMUNE INC NEXI | FY2023 | N/A | -$32.3M | N/A | N/A | — |
| Eloxx Pharmaceuticals, Inc. ELOX | FY2025 | $0 | -$6.0M | N/A | $45.3M | — |
Where NEXIMMUNE INC Ranks
Frequently Asked Questions
Is NEXIMMUNE INC profitable?
No, NEXIMMUNE INC (NEXI) reported a net loss of $32.3M in fiscal year 2023.
What is NEXIMMUNE INC's EBITDA?
NEXIMMUNE INC (NEXI) had EBITDA of -$31.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does NEXIMMUNE INC have?
As of fiscal year 2023, NEXIMMUNE INC (NEXI) had $3.2M in cash and equivalents against $0 in long-term debt.
What is NEXIMMUNE INC's return on equity (ROE)?
NEXIMMUNE INC (NEXI) has a return on equity of -921.6% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
What is NEXIMMUNE INC's free cash flow?
NEXIMMUNE INC (NEXI) recorded an outflow of $31.5M in free cash flow during fiscal year 2023. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NEXIMMUNE INC's operating cash flow?
NEXIMMUNE INC (NEXI) recorded an outflow of $31.4M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are NEXIMMUNE INC's total assets?
NEXIMMUNE INC (NEXI) had $8.6M in total assets as of fiscal year 2023, including both current and long-term assets.
What are NEXIMMUNE INC's capital expenditures?
NEXIMMUNE INC (NEXI) invested $49K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does NEXIMMUNE INC spend on research and development?
NEXIMMUNE INC (NEXI) invested $19.3M in research and development during fiscal year 2023.
What is NEXIMMUNE INC's current ratio?
NEXIMMUNE INC (NEXI) had a current ratio of 1.06 as of fiscal year 2023, which is considered adequate.
What is NEXIMMUNE INC's debt-to-equity ratio?
NEXIMMUNE INC (NEXI) had a debt-to-equity ratio of 0.00 as of fiscal year 2023. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is NEXIMMUNE INC's liabilities-to-equity ratio?
NEXIMMUNE INC (NEXI) had a liabilities-to-equity ratio of 1.45 as of fiscal year 2023, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is NEXIMMUNE INC's return on assets (ROA)?
NEXIMMUNE INC (NEXI) had a return on assets of -376.4% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
How does NEXIMMUNE INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, NEXIMMUNE INC (NEXI) held $3.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $31.4M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is NEXIMMUNE INC's Piotroski F-Score?
NEXIMMUNE INC (NEXI) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NEXIMMUNE INC's earnings high quality?
NEXIMMUNE INC (NEXI) reported a net loss of $32.3M while operations used $31.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.